The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - GRAIL
Stock and Other Ownership Interests - Illumina
NHS-Galleri Trial Design: Equitable study recruitment tactics for targeted population-level screening with a multi-cancer early detection (MCED) test.
 
Charles Swanton
Stock and Other Ownership Interests - Achilles Therapeutics; Apogen Biotechnologies; Epic Sciences; GRAIL
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Illumina; Lilly; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Roche
Consulting or Advisory Role - Bicycle Therapeutics; Genentech/Roche; GRAIL; Medicxi; Metabomed; Roche; Sarah Cannon Research Institute
Research Funding - Archer; AstraZeneca; BMS; Boehringer Ingelheim; Ono Pharmaceutical; Pfizer; Roche
Patents, Royalties, Other Intellectual Property - Founder of Achilles Therapeutics: a biotechnology company funded by Syncona/Wellcome Trust to target clonal Neoantigens through vaccine and cell therapy approaches; Immune checkpoint intervention in cancer (PCT/EP2016/071471),; Method for determining whether an HLA allele is lost in a tumour (PCT/GB2018/052004); Method for identifying responders to cancer treatment (PCT/GB2018/)051912); Method for treating cancer (PCT/EP2016/059401).; Method for treating cancer based on identification of clonal neo-antigens (PCT/EP2016/059401); Method of detecting tumour recurrence (PCT/GB2017/053289); Method of identifying insertion/deletion mutation targets (PCT/GB2018/051892); Method of predicting survival rates for cancer patients (PCT/GB2020/050221); Method of treating cancer by targeting insertion/deletion mutations (PCT/GB2018/051893); Methods for lung cancer detection (PCT/US2017/028013)
(OPTIONAL) Uncompensated Relationships - AstraZeneca (Inst)
 
Richard D Neal
Consulting or Advisory Role - GRAIL; GRAIL (Inst)
 
Peter W. M. Johnson
Honoraria - Epizyme; Genmab; InCyte
Consulting or Advisory Role - Epizyme
Patents, Royalties, Other Intellectual Property - Combined use of Fc gamma RIIb (CD32b) and CD20 - specific antibodies. WO Patent, PCT/GB2011/051572; EU11760819.0
 
Christina Clarke Dur
Employment - GRAIL
Stock and Other Ownership Interests - GRAIL; Illumina
 
Stephanie A Hamilton
Employment - GRAIL; GRAIL
Stock and Other Ownership Interests - GRAIL; GRAIL
 
Nan Zhang
Employment - GRAIL
Stock and Other Ownership Interests - GRAIL
 
Harpal Kumar
No Relationships to Disclose
 
Peter Sasieni
Consulting or Advisory Role - GRAIL; Roche Molecular Diagnostics
Research Funding - GRAIL (Inst)
Expert Testimony - Dr. Reddy's Laboratories; Mylan; Sandoz; Teva